Monalizumab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Monalizumab
- anti nkg2a
- Anti-NKG2A
- durvalumab monalizumab
- humz270
- HUMZ270
- immunoglobulin g4 anti human nkg2a cd94 receptor human mouse monoclonal humz270 heavy chain disulfide with human mouse monoclonal humz270 light chain dimer
- immunoglobulin g4 kappa anti homo sapiens klrc1 killer cell lectin like receptor subfamily c member 1 nkg2 a nkg2a cd159a cd94 humanized monoclonal antibody gamma4 heavy chain 1 452 humanized vh homo sapiens ighv1 18 01 89 80 ighd ighj2 01 r120 q 117 l123 t 130 8 8 18 1 125 ighg4 01 ch1 126 223 hinge s10 p 233 224 235 ch2 236 345 ch3 346 450 chs 451 452 126 452 139 214 disulfide with kappa light chain 1 214 humanized v kappa homo sapiens igkv1 39 01 87 40 igkj4 01 6 3 9 1 107 homo sapiens igkc 01 km3 108 214 dimer 231 231 234 234 bisdisulfide
- Immunoglobulin G4-kappa, anti-[Homo sapiens KLRC1 (killer cell lectin-like receptor subfamily C member 1, NKG2-A, NKG2A, CD159a, CD94)], humanized monoclonal antibody; gamma4 heavy chain (1-452) [humanized VH (Homo sapiens IGHV1-18*01 (89.80%)-(IGHD)-IGHJ2*01 R120>Q(117), L123>T(130))[8.8.18](1-125)), IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452))(126-452)],(139-214’)-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (87.40%) – IGKJ4*01) [6.3.9] (1’-107’)-Homo sapiens IGKC*01, Km3 (108’-214’)]; dimer (231-231’’: 234-234’’)-bisdisulfide
- Immunoglobulin G4, anti-(human NKG2A/CD94 receptor) (human-mouse monoclonal humZ270 heavy chain), disulfide with human-mouse monoclonal humZ270 light chain, dimer
- iph 2201
- iph 2201 anti nkg2a
- Iph-2201
- IPH-2201 (ANTI-NKG2A)
- iph2201
- Iph2201
- IPH2201
- monalizumab
- Monalizumab
- Monalizumab (IPH2201)
- monalizumab [INN]
- MONALIZUMAB [USAN]
- Monalizumab [WHO-DD]
- monalizumab inn
- monalizumab usan
- monalizumab who dd
And 10 more, listed on the interactive page.
- CAS registry numbers
- 1228763-95-8
- ChEMBL ID
- CHEMBL4297787
- FDA ingredient codes (UNII)
- 3ZXZ2V0588
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- monalizumab
- Type
- Antibody
- Drug name stem
- -mab; -mab
- Action
- Binding
- Action type
- Binding
- Target
- killer cell lectin like receptor C1 (CD159a)
- Gene symbol
- KLRC1
- Protein identifier
- P26715
- Median affinity
- 10.57
- Affinity units
- pKd
- Primary target
- Yes
- Mechanism
- NKG2-A/NKG2-B type II integral membrane protein inhibitor
- Action type
- Inhibitor
- Target
- NKG2-A/NKG2-B type II integral membrane protein
- Protein identifier
- P26715
Open Targets mechanisms
- Mechanism
- NKG2-A/NKG2-B type II integral membrane protein inhibitor
- Action type
- Inhibitor
- Target
- NKG2-A/NKG2-B type II integral membrane protein
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004284
- Subject identifier
- D006258
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Genital Neoplasms, Female
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0021148
- Subject identifier
- D005833
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000095
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000199
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006859
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004958
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005028
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005627
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018881
- Highest recorded phase
- 2
And 3 more, listed on the interactive page.
- NCT02331875
- NCT02459301
- NCT02557516
- NCT02643550
- NCT02671435
- NCT04333914
- NCT02921685
- NCT03088059
- NCT03794544
- NCT03801902
- NCT03822351
- NCT03833440
- NCT05061550
- NCT05221840
- NCT04145193
- NCT04307329
- NCT04590963
- NCT05903092
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (24)
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
- Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
- Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
- Biomarker-based Study in R/M SCCHN
- Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
- Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
- Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
- Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
- Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
- Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
In development for (14)
- B-cell chronic lymphocytic leukemia Phase 1
- Breast cancer Phase 2
- Cancer Phase 2
- Colorectal cancer Phase 2
- COVID-19 Phase 2
- Female reproductive system neoplasm Phase 1
- Head and neck squamous cell carcinoma Phase 3
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 3
- Oral cavity squamous cell carcinoma Phase 1
- Rheumatoid arthritis Phase 2
- Small cell lung carcinoma Phase 2
- Squamous cell carcinoma Phase 3
- Upper aerodigestive tract neoplasm Phase 1
Other linked conditions (1)
Targets (1)
- KLRC1 NKG2-A/NKG2-B type II integral membrane protein inhibitor